Evolution of Nanoparticle Protein Corona across the Blood-Brain Barrier.

Engineered nanoparticles offer the chance to improve drug transport and delivery through biological barriers, exploiting the possibility to leave the blood circulation and traverse the endothelial vascular bed, blood-brain barrier (BBB) included, to reach their target. It is known that nanoparticles gather molecules on their surface upon contact with biological fluids, forming the "protein corona", which can affect their fate and therapeutic/diagnostic performance, yet no information on the corona's evolution across the barrier has been gathered so far. Using a cellular model of the BBB and gold nanoparticles, we show that the composition of the corona undergoes dramatic quantitative and qualitative molecular modifications during passage from the "blood" to the "brain" side, while it is stable once beyond the BBB. Thus, we demonstrate that the nanoparticle corona dynamically and drastically evolves upon crossing the BBB and that its initial composition is not predictive of nanoparticle fate and performance once beyond the barrier at the target organ.

[1]  Shabir Hassan,et al.  Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine. , 2014, Journal of nanoscience and nanotechnology.

[2]  Peiyu Pu,et al.  SURFACE MULTI-FUNCTIONALIZATION OF POLY(LACTIC ACID) NANOPARTICLES AND C6 GLIOMA CELL TARGETING in vivo , 2009 .

[3]  M. Cipolla The Cerebral Circulation , 2016 .

[4]  Korsmeyer Richard Wilker Critical questions in development of targeted nanoparticle therapeutics , 2016 .

[5]  M. Wolfert,et al.  Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells. , 2016, Chemistry.

[6]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[7]  B. Dahlbäck,et al.  The nanoparticle protein corona formed in human blood or human blood fractions , 2017, PloS one.

[8]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  M. Kanoh,et al.  Serum Matrix Metalloproteinase-2 Levels Indicate Blood–CSF Barrier Damage in Patients with Infectious Meningitis , 2008, Inflammation.

[10]  Krunal K. Mehta,et al.  Biomineralized anisotropic gold microplate-macrophage interactions reveal frustrated phagocytosis-like phenomenon: a novel paclitaxel drug delivery vehicle. , 2014, ACS applied materials & interfaces.

[11]  Mojca Pavlin,et al.  Dispersion of Nanoparticles in Different Media Importantly Determines the Composition of Their Protein Corona , 2017, PloS one.

[12]  F. Stellacci,et al.  A centrifugation-based physicochemical characterization method for the interaction between proteins and nanoparticles , 2016, Nature Communications.

[13]  Nathalie Y. R. Agar,et al.  Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents , 2017, Nature Communications.

[14]  Nicholas A Peppas,et al.  A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  V. Muzykantov,et al.  Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.

[16]  G. Sancini,et al.  The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[17]  L. Campbell,et al.  Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood–brain barrier model for drug uptake and transport studies , 2003, Brain Research.

[18]  R. Upadhyay Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier , 2014, BioMed research international.

[19]  M. Masserini,et al.  Liposomes functionalized to overcome the blood–brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model , 2013, International journal of nanomedicine.

[20]  F. Stellacci,et al.  Lipid tail protrusions mediate the insertion of nanoparticles into model cell membranes , 2014, Nature Communications.

[21]  E. Tasciotti,et al.  Mesoporous silica nanoparticles trigger mitophagy in endothelial cells and perturb neuronal network activity in a size- and time-dependent manner , 2017, International journal of nanomedicine.

[22]  Beom-Jin Lee,et al.  Protein corona: a new approach for nanomedicine design , 2017, International journal of nanomedicine.

[23]  Ajay-Vikram Singh,et al.  Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges. , 2014, Current pharmaceutical biotechnology.

[24]  Omid C Farokhzad,et al.  Insight into nanoparticle cellular uptake and intracellular targeting. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Samuel T. Jones,et al.  Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. , 2018 .

[26]  M. Masserini,et al.  Novel Antitransferrin Receptor Antibodies Improve the Blood-Brain Barrier Crossing Efficacy of Immunoliposomes. , 2016, Journal of pharmaceutical sciences.

[27]  G. Morelli,et al.  Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs , 2014, International journal of nanomedicine.

[28]  Lode Vereeck,et al.  Future of nanomedicine: obstacles and remedies. , 2011, Nanomedicine.

[29]  F F SAVERIO,et al.  [Cerebral circulation]. , 1954, Omnia therapeutica. Supplemento.

[30]  P. Gaillard,et al.  Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[32]  Á. Kittel,et al.  A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes , 2009, Neurochemistry International.

[33]  P. Couraud,et al.  The hCMEC/D3 cell line as a model of the human blood brain barrier , 2013, Fluids and Barriers of the CNS.

[34]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[35]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[36]  M. Sitti,et al.  Microemulsion-Based Soft Bacteria-Driven Microswimmers for Active Cargo Delivery. , 2017, ACS nano.

[37]  Erno Pungor,et al.  Proteomic Analysis for the Assessment of Different Lots of Fetal Bovine Serum as a Raw Material for Cell Culture. Part IV. Application of Proteomics to the Manufacture of Biological Drugs , 2008, Biotechnology progress.

[38]  Mauro Ferrari,et al.  Seven challenges for nanomedicine. , 2008, Nature nanotechnology.

[39]  L. Fenart,et al.  In vitro model for evaluating drug transport across the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[40]  Y. Kariya,et al.  Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus , 2017, PloS one.

[41]  Fabio Fiordaliso,et al.  Multifunctional Liposomes Reduce Brain β-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models , 2014, The Journal of Neuroscience.

[42]  K. Dawson,et al.  The Intracellular Destiny of the Protein Corona: A Study on its Cellular Internalization and Evolution. , 2016, ACS nano.

[43]  F. Magni,et al.  Intraluminal proteome and peptidome of human urinary extracellular vesicles , 2015, Proteomics. Clinical applications.

[44]  M. Masserini,et al.  The ability of liposomes, tailored for blood-brain barrier targeting, to reach the brain is dramatically affected by the disease state. , 2018, Nanomedicine.

[45]  A. Aires,et al.  Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach. , 2014, European journal of medicinal chemistry.

[46]  Jong-Min Lim,et al.  Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics , 2017, Nature Communications.

[47]  V. Torchilin,et al.  Current trends in the use of liposomes for tumor targeting. , 2013, Nanomedicine.